FLX475 Monotherapy Results in a Decrease in Tumor Microenvironment (TME) Associated Fascinol (CaF) & Endothelial Cell Gene Signatures

**FLX475** Monotherapy Enhances Expression of Gene Sets That Are Important for Favorable Anti-PD-1/PD-L1 Response

**Clinical Data**

**FLX475** Monotherapy Activity in EBV+ NKT Cell Lymphoma

**FLX475** Monotherapy Results in a Decrease in Tumor Microenvironment (TME) Associated Fascinol (CaF) & Endothelial Cell Gene Signatures

**TLR Pathway and Signatures On-treatment in TME**

**CONCLUSIONS**

Consistent with the clinical activity observed to date with **FLX475** monotherapy in EBV+ NKT cell lymphoma and with **FLX475** + pembrolizumab in CPI-naïve NSCLC, biomarker studies have demonstrated several lines of evidence supporting the proposed MOA of CCR4 antagonism:

**Tumor microenvironment**
- **FLX475** treatment results in a small increase in proportion of circulating Treg
- **FLX475** monotherapy environment in decreased Treg and CaF along with increased TLR and associated gene signatures
- **FLX475** induced gene expression changes which resemble TME of patients that responded to anti-PD-1 monotherapy
- **FLX475** conditions TME for Anti-PD-1/PD-L1 response by increasing expression of gene sets associated with immunosuppression

**Peripheral biomarkers**
- **FLX475** treatment results in a small increase in proportion of circulating Treg
- **FLX475** monotherapy environment in decreased Treg and CaF along with increased TLR and associated gene signatures
- **FLX475** induced gene expression changes which resemble TME of patients that responded to anti-PD-1 monotherapy
- **FLX475** conditions TME for Anti-PD-1/PD-L1 response by increasing expression of gene sets associated with immunosuppression

**Acknowledgments**

We would like to thank our patients, caregivers, clinical investigators and their staff as well as our colleagues at RAPT Therapeutics and scientific advisors for helpful suggestions and discussion.

This study is in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA